OBJ advocates for electromagnetic physical science

0

The medical solutions company OBJ Limited (ASX: OBJ) has published the results of a recent study on one of its ‘magnetophoresis-enhanced transdermal patches’, carried out by Professor Tony Wright of the School of Physiotherapy and Science from Curtin University’s exercise.

In the report, Professor Wright said that “it is clear that the active knee brace device containing ibuprofen (5%) with magnetophoresis produced a significantly greater reduction in pain and improvement in function than the active knee brace device. placebo device.

Mr Wright added that “this was particularly the case with movement pain” and also noted “a significant improvement in pressure pain thresholds” in patients.

Attention to detail

In the study covered by the report, each participant completed two study periods during which they received magnetophoresis-enhanced ibuprofen transdermal patches or placebo patches in random order.

The report was based on a double-blind clinical outcome study after administration of a transdermal patch of ibuprofen (5%) enhanced by magnetophoresis for 48 hours and then compared to placebo.

Study participants were “community-living volunteers” with an average of 66 and medically diagnosed painful osteoarthritis of the knee. The study sought to demonstrate that OBJ’s back-matrix hydrogel technology could be used with third-party therapeutic drugs such as ibuprofen and, in all likelihood, other drugs of a similar molecular nature.

Professor Wright’s report indicated that there were significant differences between the active patch and placebo sessions, for all primary outcome measures, “indicating that participants experienced less pain and improved function over the course of the period. 48 hour active patch session “. The report also noted that the majority of participants reported no skin reactions to placebo or active patches.

Out of a sample of 24 participants, 22 rated themselves as “better” or “much better” after the active patch treatment of OBJ.

Next Generation Technology

As a medical company, OBJ is quite unique. This is largely because it operates in the healthcare industry with an emphasis on “physical science over chemistry” to deliver new levels of product performance.

One of its other goals is to forgo all costs of reformulating and approving new ingredients, simply because they are in excess of requirements given OBJ’s non-chemical approach.

OBJ wants to achieve these feats by using magnetic arrays, electromagnetic inductors and microarrays using “diamagnetic repulsion, induced permeation and energy redirection”, as a means of delivering active ingredients to various parts of the human body.

The report released today indicates that OBJ can successfully deliver ibuprofen to patients with painful osteoarthritis of the knee, with significant potential to expand its back matrix hydrogel technology to other applications.

According to OBJ, its non-invasive approach has developed a number of physical enhancement technologies “based on the interactions between ingredient molecules and weak atomic forces,” and claims that its treatments can “alter the permeability of biological targets and non-organic “.

Its current business activities include providing a range of patented products for the pharmaceutical, healthcare and consumer goods industries that the company is potentially looking to expand over the next 12 to 24 months with several new product launches.


Source link

Leave A Reply

Your email address will not be published.